Forte Board Unanimously Recommends $77/Share argenx Tender Offer, Backed by Fairness Opinion and Detailed Financial Projections
FBRX has more than doubled off its 52-week low of $9.1.
Summary
Forte Biosciences' board unanimously recommends that shareholders tender into argenx's $77 per share all-cash tender offer, citing a 41% premium and a fairness opinion from Guggenheim Securities. The filing details the negotiation process, executive compensation, and long-range financial projections that support the deal.
Key Events · M&A and Partnerships · FBRX
-
Board Unanimously Recommends Tender Offer
The Forte board unanimously recommends shareholders accept argenx's $77 per share all-cash tender offer, which represents a 41% premium to the last unaffected closing price of $54.78 on July 24, 2026.
-
Fairness Opinion from Guggenheim Securities
Guggenheim Securities delivered a fairness opinion, concluding the $77 per share offer is fair from a financial point of view. The analysis included a discounted cash flow valuation range of $56.57 to $78.85 per share.
-
Negotiation History Reveals Price Increases
argenx's initial proposal on July 12 was $65 per share. The board rejected it and negotiated up to $77 per share, a 12% increase, which the board believes is argenx's best and final offer.
-
Executive Golden Parachute Compensation Disclosed
CEO Paul Wagner could receive an estimated $89.4 million in total compensation upon a change-in-control termination, including $86.8 million from accelerated equity vesting and $2.2 million in cash severance.
Analysis · FBRX · Life Sciences
The board's formal recommendation and the newly disclosed details—including the fairness opinion, long-range financial projections, and executive golden parachute compensation—solidify the $2.2 billion acquisition. The $77 per share all-cash offer represents a 41% premium to the last unaffected trading price and a 29% premium to the 52-week high. The filing reveals the negotiation history, with argenx raising its bid from $65 to $77 per share, and provides the financial analysis supporting the board's view that this is the best reasonably obtainable value. The disclosure of management's projections, which assume no revenue until 2030 and significant future financing needs, underscores the execution risk the company would face as a standalone entity, making the certain cash offer more compelling.
At the time of this filing, FBRX was trading at $76.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $9.10 to $77.20. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.